Source comparison
Sermorelin + GHRP-2 vs Other GH Secretagogue Combinations
Sermorelin + GHRP-2 GHRH receptor + ghrelin receptor dual activation 2.5–3.5× additive prediction Mild transient hunger, rare water retention Established clinical data, predictable dose-response curve, lower cost than CJC-1295 Best option for protocols priorit
This comparison does not assign a generated winner or score.
- Sermorelin + GHRP-2
- GHRH receptor + ghrelin receptor dual activation
- 2.5–3.5× additive prediction
- Mild transient hunger, rare water retention
- Established clinical data, predictable dose-response curve, lower cost than CJC-1295
- Best option for protocols prioritising synergy with minimal complexity
- Sermorelin + Ipamorelin
- GHRH receptor + selective ghrelin receptor (no ghrelin side effects)
- 2.0–2.8× additive prediction
- Minimal. Ipamorelin does not increase cortisol or prolactin
- Cleaner side effect profile, no hunger or lethargy, easier to dose pre-sleep
- Recommended for protocols where GHRP-2 ghrelin effects (hunger, water retention) are undesirable
- CJC-1295 (DAC) + GHRP-2
- Long-acting GHRH analog + ghrelin receptor
- 3.0–4.0× additive prediction but sustained rather than pulsatile
- Significantly higher risk of prolactin elevation, blunted natural GH pulsatility over time
- Requires dosing only 1–2× per week, but continuous elevation disrupts natural feedback loops
- Not recommended for long-term use. DAC formulation eliminates pulsatile release, which is essential for physiological GH signaling
- Sermorelin + Hexarelin
- GHRH receptor + highly potent ghrelin receptor agonist
- 3.5–4.5× additive prediction
- High risk of desensitisation after 4–6 weeks, cortisol and prolactin elevation
- Strongest synergy of any combination, but diminishing returns and side effects limit practical use
- Reserved for short-term intensive protocols. Not sustainable beyond 6 weeks due to rapid receptor downregulation
- Sermorelin alone
- GHRH receptor only
- Baseline (no synergy)
- Minimal. Well-tolerated in clinical trials
- Simple single-peptide protocol, no interaction complexity
- Effective for mild GH deficiency or low-complexity protocols, but synergy-dependent results require combination therapy